Idenix rally may be linked to AASLD meeting: Deutsche


Deutsche's Alethia Young thinks the rally in shares of Idenix Pharmaceuticals (IDIX +41%) may be attributable to the upcoming AASLD meeting which begins this weekend.

Here's Young: "IDIX has noted that they are not interested in an exclusive arrangement with JNJ or anyone else [but] we would assume that any HCV developer would be interested in a nuke."

IDIX's HELIX-1 trial is evaluating the company's NS5A inhibitor, samatasvirin in combination with JNJ's simeprevir.

Deutsche has the shares at Hold.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs